sanofi nasdaq - Search News

News

Sanofi buys Vigil Neuroscience for $470m

Sanofi to buy Vigil Neuroscience in $470M deal (update)

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) for $470M in cash, potentially reaching $600M with milestone payments. Following a trading halt,

Insider Monkey on MSN · 3d

Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer’s treatment.

AOL · 2d

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

Vigil Neuroscience, Inc. (NASDAQ:VIGL) on Wednesday disclosed that it entered a deal to be acquired by Sanofi (NASDAQ:SNY) for an equity value of approximately $470 million (on a fully diluted basis).

15hon MSN

Key deals this week: Foxconn, Sanofi, Honeywell, Adriatic Metals, Informatica and more

Foxconn Technology (OTCPK:FXCOF) is among potential bidders for UTAC Holdings in a transaction that could value the Singapore-based semiconductor assembly and testing company at about $3 billion.

Nasdaq4d

Sanofi to Acquire Vigil Neuroscience for Up to $10.00 per Share in Cash; Transaction Expected to Enhance Alzheimer’s Drug Development

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Sanofi buys Vigil Neuroscience for $470m

Trending now